Neuland Laboratories Ltd Q4FY21 consolidated PAT slides QoQ to Rs. 17.29 crore

NEULAND LABORATORIES LTD. has reported financial results for the period ended March 31, 2021.

Financial Results (Q4 FY20-21) - QoQ Comparison

The company has reported total income of Rs.259.30 crores during the period ended March 31, 2021 as compared to Rs.245.58 crores during the period ended December 31, 2020.

The company has posted net profit / (loss) of Rs.17.29 crores for the period ended March 31, 2021 as against net profit / (loss) of Rs.26.73 crores for the period ended December 31, 2020.

The company has reported EPS of Rs.13.48 for the period ended March 31, 2021 as compared to Rs.20.84 for the period ended December 31, 2020.

Financials	Q4 FY20-21	Q3 FY20-21	% Change
Total Income	₹ 259.30 crs	₹ 245.58 crs	5.59%
Net Profit	₹ 17.29 crs	₹ 26.73 crs	-35.32%
EPS	₹ 13.48	₹ 20.84	-35.32%

Financial Results (Q4 FY20-21) - YoY Comparison

The company has reported total income of Rs.259.30 crores during the period ended March 31, 2021 as compared to Rs.193.41 crores during the period ended March 31, 2020.

The company has posted net profit / (loss) of Rs.17.29 crores for the period ended March 31, 2021 as against net profit / (loss) of Rs.(9.29) crores for the period ended March 31, 2020.

The company has reported EPS of Rs.13.48 for the period ended March 31, 2021 as compared to Rs.(7.25) for the period ended March 31, 2020.

Financials	Q4 FY20-21	Q4 FY19-20	% Change
Total Income	₹ 259.30 crs	₹ 193.41 crs	34.07%
Net Profit	₹ 17.29 crs	₹ (9.29) crs	286.11%
EPS	₹ 13.48	₹ (7.25)	285.93%

Financial Results (Year ended FY 20-21) - YoY Comparison

The company has reported total income of Rs.953 crores during the 12 months period ended March 31, 2021 as compared to Rs.766.59 crores during the 12 months period ended March 31, 2020.

The company has posted net profit / (loss) of Rs.80.63 crores for the 12 months period ended March 31, 2021 as against net profit / (loss) of Rs.16.21 crores for the 12 months period ended March 31, 2020.

The company has reported EPS of Rs.62.85 for the 12 months period ended March 31, 2021 as compared to Rs.12.63 for the 12 months period ended March 31, 2020.

Financials	Year Ended FY20-21	Year Ended FY19-20	% Change
Total Income	₹ 953 crs	₹ 766.59 crs	24.32%
Net Profit	₹ 80.63 crs	₹ 16.21 crs	397.41%
EPS	₹ 62.85	₹12.63	397.62%

Commenting on the performance Mr. Sucheth Davuluri, Vice-Chairman and Chief Executive Officer of the Company said, "We are pleased with the performance of the Company in this fiscal which was on the back of challenging conditions in the aftermath of the onset of COVID19. The resilience and the commitment to rise to the occasion and execute our plans is a testimony to the fighting spirit of the team. While we are facing headwinds from the second wave of COVID19, we remain committed to our long-term aspirations and believe that our differentiated focus on complex APIs and the CMS business will drive sustainable growth."

In addition, Mr. Saharsh Davuluri, Vice Chairman and Managing Director, Neuland Labs added "The numbers indicate the strong performance of our business and operating leverage kicking as seen by the improvement in margins. We are happy with the growth in the CMS business by about 42%, which was driven by increase in revenue from both baseline and development projects. The CMS projects in the pipeline have reached a critical mass and this would drive the medium to long term growth with the increased traction. We expect Unit 3 to achieve critical scale by the end of this fiscal and that should be another lever of growth for the Company."

Shares of NEULAND LABORATORIES LTD. was last trading in BSE at Rs.2677 as compared to the previous close of Rs. 2682.9. The total number of shares traded during the day was 6709 in over 1347 trades.

The stock hit an intraday high of Rs. 2729.3 and intraday low of 2662.85. The net turnover during the day was Rs. 18126444.

Source : Equity Bulls

Keywords